nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—ABCB1—Dactinomycin—muscle cancer	0.0595	0.153	CbGbCtD
Lapatinib—CYP3A5—Vincristine—muscle cancer	0.0563	0.145	CbGbCtD
Lapatinib—CYP3A5—Etoposide—muscle cancer	0.0516	0.133	CbGbCtD
Lapatinib—CYP2C8—Etoposide—muscle cancer	0.0496	0.128	CbGbCtD
Lapatinib—ABCB1—Vincristine—muscle cancer	0.0366	0.0944	CbGbCtD
Lapatinib—ABCB1—Etoposide—muscle cancer	0.0336	0.0865	CbGbCtD
Lapatinib—ABCB1—Doxorubicin—muscle cancer	0.0229	0.059	CbGbCtD
Lapatinib—ABCB1—Methotrexate—muscle cancer	0.0222	0.0572	CbGbCtD
Lapatinib—CYP3A4—Vincristine—muscle cancer	0.0219	0.0566	CbGbCtD
Lapatinib—CYP3A4—Etoposide—muscle cancer	0.0201	0.0518	CbGbCtD
Lapatinib—CYP3A4—Doxorubicin—muscle cancer	0.0137	0.0354	CbGbCtD
Lapatinib—Left ventricular ejection fraction decreased—Doxorubicin—muscle cancer	0.0107	0.0572	CcSEcCtD
Lapatinib—Metastatic disease—Doxorubicin—muscle cancer	0.00774	0.0413	CcSEcCtD
Lapatinib—Cardiotoxicity—Etoposide—muscle cancer	0.0073	0.039	CcSEcCtD
Lapatinib—ERBB2—embryo—muscle cancer	0.00634	0.0448	CbGeAlD
Lapatinib—ERBB4—embryo—muscle cancer	0.00634	0.0448	CbGeAlD
Lapatinib—Paronychia—Methotrexate—muscle cancer	0.00594	0.0317	CcSEcCtD
Lapatinib—TAP1—cardiac atrium—muscle cancer	0.00588	0.0416	CbGeAlD
Lapatinib—PIK3C2B—cardiac atrium—muscle cancer	0.00552	0.0391	CbGeAlD
Lapatinib—Ejection fraction decreased—Doxorubicin—muscle cancer	0.00543	0.029	CcSEcCtD
Lapatinib—TAP1—tendon—muscle cancer	0.00513	0.0363	CbGeAlD
Lapatinib—ERBB2—smooth muscle tissue—muscle cancer	0.00498	0.0353	CbGeAlD
Lapatinib—TAP1—bone marrow—muscle cancer	0.00497	0.0352	CbGeAlD
Lapatinib—PIK3C2B—tendon—muscle cancer	0.00482	0.0341	CbGeAlD
Lapatinib—ERBB2—renal system—muscle cancer	0.0048	0.0339	CbGeAlD
Lapatinib—TAP1—vagina—muscle cancer	0.00476	0.0337	CbGeAlD
Lapatinib—PI4KB—smooth muscle tissue—muscle cancer	0.00467	0.033	CbGeAlD
Lapatinib—PIK3C2B—bone marrow—muscle cancer	0.00466	0.033	CbGeAlD
Lapatinib—Metastatic neoplasm—Doxorubicin—muscle cancer	0.00465	0.0248	CcSEcCtD
Lapatinib—PI4KB—renal system—muscle cancer	0.00449	0.0318	CbGeAlD
Lapatinib—PIK3C2B—vagina—muscle cancer	0.00447	0.0316	CbGeAlD
Lapatinib—ERBB4—cardiac atrium—muscle cancer	0.0043	0.0304	CbGeAlD
Lapatinib—TAP1—testis—muscle cancer	0.00425	0.03	CbGeAlD
Lapatinib—PIK3C2B—head—muscle cancer	0.00413	0.0292	CbGeAlD
Lapatinib—PI4KB—cardiac atrium—muscle cancer	0.00402	0.0285	CbGeAlD
Lapatinib—PIK3C2B—testis—muscle cancer	0.00399	0.0282	CbGeAlD
Lapatinib—Cardiotoxicity—Doxorubicin—muscle cancer	0.00378	0.0202	CcSEcCtD
Lapatinib—ERBB4—tendon—muscle cancer	0.00374	0.0265	CbGeAlD
Lapatinib—PIK3C2B—Vindesine—Vincristine—muscle cancer	0.00353	0.289	CbGdCrCtD
Lapatinib—PI4KB—tendon—muscle cancer	0.00351	0.0248	CbGeAlD
Lapatinib—ERBB4—vagina—muscle cancer	0.00348	0.0246	CbGeAlD
Lapatinib—PI4KB—bone marrow—muscle cancer	0.0034	0.024	CbGeAlD
Lapatinib—PI4KB—vagina—muscle cancer	0.00325	0.023	CbGeAlD
Lapatinib—ERBB2—head—muscle cancer	0.00321	0.0227	CbGeAlD
Lapatinib—ERBB4—head—muscle cancer	0.00321	0.0227	CbGeAlD
Lapatinib—Peripheral sensory neuropathy—Doxorubicin—muscle cancer	0.00312	0.0167	CcSEcCtD
Lapatinib—Mucosal inflammation—Etoposide—muscle cancer	0.0031	0.0166	CcSEcCtD
Lapatinib—ERBB2—testis—muscle cancer	0.0031	0.0219	CbGeAlD
Lapatinib—ERBB4—testis—muscle cancer	0.0031	0.0219	CbGeAlD
Lapatinib—Hepatotoxicity—Dactinomycin—muscle cancer	0.00308	0.0164	CcSEcCtD
Lapatinib—PI4KB—head—muscle cancer	0.00301	0.0213	CbGeAlD
Lapatinib—PI4KB—testis—muscle cancer	0.0029	0.0205	CbGeAlD
Lapatinib—Nail disorder—Etoposide—muscle cancer	0.00265	0.0142	CcSEcCtD
Lapatinib—EGFR—testis—muscle cancer	0.00263	0.0186	CbGeAlD
Lapatinib—Interstitial lung disease—Etoposide—muscle cancer	0.00243	0.013	CcSEcCtD
Lapatinib—PIK3C2B—Vinorelbine—Vincristine—muscle cancer	0.00223	0.182	CbGdCrCtD
Lapatinib—Hepatotoxicity—Etoposide—muscle cancer	0.00223	0.0119	CcSEcCtD
Lapatinib—PIK3C2B—Podofilox—Etoposide—muscle cancer	0.00223	0.182	CbGdCrCtD
Lapatinib—Mucosal inflammation—Methotrexate—muscle cancer	0.00186	0.00994	CcSEcCtD
Lapatinib—ERBB2—Podofilox—Etoposide—muscle cancer	0.00183	0.15	CbGdCrCtD
Lapatinib—Mucosal inflammation—Doxorubicin—muscle cancer	0.00161	0.0086	CcSEcCtD
Lapatinib—Nail disorder—Methotrexate—muscle cancer	0.00159	0.00848	CcSEcCtD
Lapatinib—Pain in extremity—Vincristine—muscle cancer	0.00154	0.00823	CcSEcCtD
Lapatinib—PIK3C2B—Vinblastine—Vincristine—muscle cancer	0.00153	0.125	CbGdCrCtD
Lapatinib—Interstitial lung disease—Methotrexate—muscle cancer	0.00145	0.00777	CcSEcCtD
Lapatinib—Dehydration—Vincristine—muscle cancer	0.00143	0.00765	CcSEcCtD
Lapatinib—Neutropenia—Dactinomycin—muscle cancer	0.00139	0.00744	CcSEcCtD
Lapatinib—Nail disorder—Doxorubicin—muscle cancer	0.00137	0.00734	CcSEcCtD
Lapatinib—Pneumonia—Dactinomycin—muscle cancer	0.00134	0.00714	CcSEcCtD
Lapatinib—Hepatotoxicity—Methotrexate—muscle cancer	0.00133	0.00712	CcSEcCtD
Lapatinib—CYP2C8—renal system—muscle cancer	0.0013	0.00922	CbGeAlD
Lapatinib—Stomatitis—Dactinomycin—muscle cancer	0.0013	0.00692	CcSEcCtD
Lapatinib—Cardiac failure—Etoposide—muscle cancer	0.00128	0.00683	CcSEcCtD
Lapatinib—Neutropenia—Vincristine—muscle cancer	0.00124	0.00665	CcSEcCtD
Lapatinib—Pneumonia—Vincristine—muscle cancer	0.00119	0.00638	CcSEcCtD
Lapatinib—CYP3A5—renal system—muscle cancer	0.00118	0.00833	CbGeAlD
Lapatinib—Neuropathy peripheral—Vincristine—muscle cancer	0.00116	0.00622	CcSEcCtD
Lapatinib—Stomatitis—Vincristine—muscle cancer	0.00116	0.00618	CcSEcCtD
Lapatinib—Hyperbilirubinaemia—Methotrexate—muscle cancer	0.00113	0.00605	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Etoposide—muscle cancer	0.0011	0.00588	CcSEcCtD
Lapatinib—CYP2C19—vagina—muscle cancer	0.00108	0.00765	CbGeAlD
Lapatinib—Blood disorder—Doxorubicin—muscle cancer	0.00107	0.0057	CcSEcCtD
Lapatinib—Alopecia—Dactinomycin—muscle cancer	0.00105	0.00563	CcSEcCtD
Lapatinib—Connective tissue disorder—Vincristine—muscle cancer	0.00105	0.00559	CcSEcCtD
Lapatinib—Neoplasm malignant—Doxorubicin—muscle cancer	0.00104	0.00558	CcSEcCtD
Lapatinib—Neutropenia—Etoposide—muscle cancer	0.00101	0.00539	CcSEcCtD
Lapatinib—Cardiac disorder—Vincristine—muscle cancer	0.000989	0.00528	CcSEcCtD
Lapatinib—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.00098	0.00524	CcSEcCtD
Lapatinib—Pneumonia—Etoposide—muscle cancer	0.000967	0.00517	CcSEcCtD
Lapatinib—Angiopathy—Vincristine—muscle cancer	0.000967	0.00517	CcSEcCtD
Lapatinib—Infestation NOS—Etoposide—muscle cancer	0.000962	0.00514	CcSEcCtD
Lapatinib—Infestation—Etoposide—muscle cancer	0.000962	0.00514	CcSEcCtD
Lapatinib—Mediastinal disorder—Vincristine—muscle cancer	0.00096	0.00513	CcSEcCtD
Lapatinib—Anaemia—Dactinomycin—muscle cancer	0.00096	0.00513	CcSEcCtD
Lapatinib—CYP2C8—vagina—muscle cancer	0.000944	0.00668	CbGeAlD
Lapatinib—Blood bilirubin increased—Doxorubicin—muscle cancer	0.000943	0.00504	CcSEcCtD
Lapatinib—Neuropathy peripheral—Etoposide—muscle cancer	0.000943	0.00504	CcSEcCtD
Lapatinib—Alopecia—Vincristine—muscle cancer	0.000942	0.00503	CcSEcCtD
Lapatinib—Stomatitis—Etoposide—muscle cancer	0.000937	0.00501	CcSEcCtD
Lapatinib—Mental disorder—Vincristine—muscle cancer	0.000934	0.00499	CcSEcCtD
Lapatinib—Leukopenia—Dactinomycin—muscle cancer	0.000929	0.00497	CcSEcCtD
Lapatinib—Hepatobiliary disease—Etoposide—muscle cancer	0.000909	0.00486	CcSEcCtD
Lapatinib—Back pain—Vincristine—muscle cancer	0.000897	0.00479	CcSEcCtD
Lapatinib—ERBB2—Epirubicin—Doxorubicin—muscle cancer	0.000884	0.0723	CbGdCrCtD
Lapatinib—Myalgia—Dactinomycin—muscle cancer	0.000884	0.00472	CcSEcCtD
Lapatinib—CYP3A4—renal system—muscle cancer	0.000883	0.00625	CbGeAlD
Lapatinib—Anaemia—Vincristine—muscle cancer	0.000857	0.00458	CcSEcCtD
Lapatinib—CYP3A5—vagina—muscle cancer	0.000852	0.00603	CbGeAlD
Lapatinib—CYP2C8—testis—muscle cancer	0.000843	0.00596	CbGeAlD
Lapatinib—Infection—Dactinomycin—muscle cancer	0.000842	0.0045	CcSEcCtD
Lapatinib—Leukopenia—Vincristine—muscle cancer	0.00083	0.00444	CcSEcCtD
Lapatinib—ABCB1—embryo—muscle cancer	0.000826	0.00584	CbGeAlD
Lapatinib—Renal failure acute—Methotrexate—muscle cancer	0.00081	0.00433	CcSEcCtD
Lapatinib—Anorexia—Dactinomycin—muscle cancer	0.000808	0.00432	CcSEcCtD
Lapatinib—Cardiac disorder—Etoposide—muscle cancer	0.000801	0.00428	CcSEcCtD
Lapatinib—Myalgia—Vincristine—muscle cancer	0.00079	0.00422	CcSEcCtD
Lapatinib—Angiopathy—Etoposide—muscle cancer	0.000783	0.00418	CcSEcCtD
Lapatinib—Immune system disorder—Etoposide—muscle cancer	0.00078	0.00417	CcSEcCtD
Lapatinib—Mediastinal disorder—Etoposide—muscle cancer	0.000778	0.00416	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000772	0.00412	CcSEcCtD
Lapatinib—Alopecia—Etoposide—muscle cancer	0.000763	0.00408	CcSEcCtD
Lapatinib—Anaphylactic shock—Vincristine—muscle cancer	0.000757	0.00404	CcSEcCtD
Lapatinib—Infection—Vincristine—muscle cancer	0.000752	0.00402	CcSEcCtD
Lapatinib—Nervous system disorder—Vincristine—muscle cancer	0.000742	0.00397	CcSEcCtD
Lapatinib—Decreased appetite—Dactinomycin—muscle cancer	0.000737	0.00394	CcSEcCtD
Lapatinib—Fatigue—Dactinomycin—muscle cancer	0.000731	0.0039	CcSEcCtD
Lapatinib—Back pain—Etoposide—muscle cancer	0.000727	0.00388	CcSEcCtD
Lapatinib—Anorexia—Vincristine—muscle cancer	0.000722	0.00386	CcSEcCtD
Lapatinib—Renal failure acute—Doxorubicin—muscle cancer	0.000701	0.00375	CcSEcCtD
Lapatinib—Anaemia—Etoposide—muscle cancer	0.000695	0.00371	CcSEcCtD
Lapatinib—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000693	0.0037	CcSEcCtD
Lapatinib—Hot flush—Doxorubicin—muscle cancer	0.000692	0.0037	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00069	0.00369	CcSEcCtD
Lapatinib—Menopausal symptoms—Doxorubicin—muscle cancer	0.000686	0.00366	CcSEcCtD
Lapatinib—Insomnia—Vincristine—muscle cancer	0.000685	0.00366	CcSEcCtD
Lapatinib—Leukopenia—Etoposide—muscle cancer	0.000673	0.00359	CcSEcCtD
Lapatinib—Abdominal pain—Dactinomycin—muscle cancer	0.00067	0.00358	CcSEcCtD
Lapatinib—Cardiac failure—Doxorubicin—muscle cancer	0.000663	0.00354	CcSEcCtD
Lapatinib—Decreased appetite—Vincristine—muscle cancer	0.000658	0.00352	CcSEcCtD
Lapatinib—Cough—Etoposide—muscle cancer	0.000656	0.0035	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000654	0.00349	CcSEcCtD
Lapatinib—Fatigue—Vincristine—muscle cancer	0.000653	0.00349	CcSEcCtD
Lapatinib—Constipation—Vincristine—muscle cancer	0.000647	0.00346	CcSEcCtD
Lapatinib—Pain in extremity—Doxorubicin—muscle cancer	0.000647	0.00346	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000635	0.00339	CcSEcCtD
Lapatinib—ABCB1—renal system—muscle cancer	0.000625	0.00442	CbGeAlD
Lapatinib—Hypersensitivity—Dactinomycin—muscle cancer	0.000624	0.00334	CcSEcCtD
Lapatinib—Gastrointestinal pain—Vincristine—muscle cancer	0.000619	0.00331	CcSEcCtD
Lapatinib—Anaphylactic shock—Etoposide—muscle cancer	0.000613	0.00328	CcSEcCtD
Lapatinib—Infection—Etoposide—muscle cancer	0.000609	0.00326	CcSEcCtD
Lapatinib—Asthenia—Dactinomycin—muscle cancer	0.000608	0.00325	CcSEcCtD
Lapatinib—Neutropenia—Methotrexate—muscle cancer	0.000604	0.00323	CcSEcCtD
Lapatinib—Dehydration—Doxorubicin—muscle cancer	0.000602	0.00322	CcSEcCtD
Lapatinib—Abdominal pain—Vincristine—muscle cancer	0.000598	0.0032	CcSEcCtD
Lapatinib—Skin disorder—Etoposide—muscle cancer	0.000596	0.00318	CcSEcCtD
Lapatinib—Dry skin—Doxorubicin—muscle cancer	0.000593	0.00317	CcSEcCtD
Lapatinib—Anorexia—Etoposide—muscle cancer	0.000585	0.00312	CcSEcCtD
Lapatinib—Diarrhoea—Dactinomycin—muscle cancer	0.00058	0.0031	CcSEcCtD
Lapatinib—Pneumonia—Methotrexate—muscle cancer	0.000579	0.0031	CcSEcCtD
Lapatinib—Infestation—Methotrexate—muscle cancer	0.000576	0.00308	CcSEcCtD
Lapatinib—Infestation NOS—Methotrexate—muscle cancer	0.000576	0.00308	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000571	0.00305	CcSEcCtD
Lapatinib—Stomatitis—Methotrexate—muscle cancer	0.000561	0.003	CcSEcCtD
Lapatinib—Hypersensitivity—Vincristine—muscle cancer	0.000558	0.00298	CcSEcCtD
Lapatinib—Dyspnoea—Etoposide—muscle cancer	0.000547	0.00292	CcSEcCtD
Lapatinib—Hepatobiliary disease—Methotrexate—muscle cancer	0.000545	0.00291	CcSEcCtD
Lapatinib—Epistaxis—Methotrexate—muscle cancer	0.000543	0.0029	CcSEcCtD
Lapatinib—Asthenia—Vincristine—muscle cancer	0.000543	0.0029	CcSEcCtD
Lapatinib—Vomiting—Dactinomycin—muscle cancer	0.000539	0.00288	CcSEcCtD
Lapatinib—Rash—Dactinomycin—muscle cancer	0.000534	0.00285	CcSEcCtD
Lapatinib—Decreased appetite—Etoposide—muscle cancer	0.000533	0.00285	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Etoposide—muscle cancer	0.000529	0.00283	CcSEcCtD
Lapatinib—Fatigue—Etoposide—muscle cancer	0.000529	0.00282	CcSEcCtD
Lapatinib—Constipation—Etoposide—muscle cancer	0.000524	0.0028	CcSEcCtD
Lapatinib—Neutropenia—Doxorubicin—muscle cancer	0.000523	0.00279	CcSEcCtD
Lapatinib—Diarrhoea—Vincristine—muscle cancer	0.000518	0.00277	CcSEcCtD
Lapatinib—Nausea—Dactinomycin—muscle cancer	0.000503	0.00269	CcSEcCtD
Lapatinib—Pneumonia—Doxorubicin—muscle cancer	0.000502	0.00268	CcSEcCtD
Lapatinib—Gastrointestinal pain—Etoposide—muscle cancer	0.000502	0.00268	CcSEcCtD
Lapatinib—Infestation—Doxorubicin—muscle cancer	0.000499	0.00266	CcSEcCtD
Lapatinib—Infestation NOS—Doxorubicin—muscle cancer	0.000499	0.00266	CcSEcCtD
Lapatinib—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000489	0.00261	CcSEcCtD
Lapatinib—Stomatitis—Doxorubicin—muscle cancer	0.000486	0.0026	CcSEcCtD
Lapatinib—Abdominal pain—Etoposide—muscle cancer	0.000485	0.00259	CcSEcCtD
Lapatinib—Vomiting—Vincristine—muscle cancer	0.000481	0.00257	CcSEcCtD
Lapatinib—Cardiac disorder—Methotrexate—muscle cancer	0.00048	0.00256	CcSEcCtD
Lapatinib—Rash—Vincristine—muscle cancer	0.000477	0.00255	CcSEcCtD
Lapatinib—Dermatitis—Vincristine—muscle cancer	0.000477	0.00255	CcSEcCtD
Lapatinib—Headache—Vincristine—muscle cancer	0.000474	0.00253	CcSEcCtD
Lapatinib—ABCB1—bone marrow—muscle cancer	0.000473	0.00334	CbGeAlD
Lapatinib—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000472	0.00252	CcSEcCtD
Lapatinib—Epistaxis—Doxorubicin—muscle cancer	0.00047	0.00251	CcSEcCtD
Lapatinib—Angiopathy—Methotrexate—muscle cancer	0.000469	0.00251	CcSEcCtD
Lapatinib—Immune system disorder—Methotrexate—muscle cancer	0.000467	0.0025	CcSEcCtD
Lapatinib—Mediastinal disorder—Methotrexate—muscle cancer	0.000466	0.00249	CcSEcCtD
Lapatinib—Alopecia—Methotrexate—muscle cancer	0.000457	0.00244	CcSEcCtD
Lapatinib—Mental disorder—Methotrexate—muscle cancer	0.000453	0.00242	CcSEcCtD
Lapatinib—ABCB1—vagina—muscle cancer	0.000453	0.0032	CbGeAlD
Lapatinib—Hypersensitivity—Etoposide—muscle cancer	0.000452	0.00241	CcSEcCtD
Lapatinib—Malnutrition—Methotrexate—muscle cancer	0.00045	0.0024	CcSEcCtD
Lapatinib—Nausea—Vincristine—muscle cancer	0.00045	0.0024	CcSEcCtD
Lapatinib—Asthenia—Etoposide—muscle cancer	0.00044	0.00235	CcSEcCtD
Lapatinib—Connective tissue disorder—Doxorubicin—muscle cancer	0.00044	0.00235	CcSEcCtD
Lapatinib—Back pain—Methotrexate—muscle cancer	0.000435	0.00233	CcSEcCtD
Lapatinib—Pruritus—Etoposide—muscle cancer	0.000434	0.00232	CcSEcCtD
Lapatinib—Diarrhoea—Etoposide—muscle cancer	0.00042	0.00224	CcSEcCtD
Lapatinib—ABCB1—head—muscle cancer	0.000418	0.00296	CbGeAlD
Lapatinib—Anaemia—Methotrexate—muscle cancer	0.000416	0.00222	CcSEcCtD
Lapatinib—Cardiac disorder—Doxorubicin—muscle cancer	0.000416	0.00222	CcSEcCtD
Lapatinib—Angiopathy—Doxorubicin—muscle cancer	0.000406	0.00217	CcSEcCtD
Lapatinib—Immune system disorder—Doxorubicin—muscle cancer	0.000404	0.00216	CcSEcCtD
Lapatinib—ABCB1—testis—muscle cancer	0.000404	0.00286	CbGeAlD
Lapatinib—Mediastinal disorder—Doxorubicin—muscle cancer	0.000404	0.00216	CcSEcCtD
Lapatinib—Leukopenia—Methotrexate—muscle cancer	0.000403	0.00215	CcSEcCtD
Lapatinib—Alopecia—Doxorubicin—muscle cancer	0.000396	0.00211	CcSEcCtD
Lapatinib—Cough—Methotrexate—muscle cancer	0.000393	0.0021	CcSEcCtD
Lapatinib—Mental disorder—Doxorubicin—muscle cancer	0.000392	0.0021	CcSEcCtD
Lapatinib—Vomiting—Etoposide—muscle cancer	0.00039	0.00208	CcSEcCtD
Lapatinib—Malnutrition—Doxorubicin—muscle cancer	0.00039	0.00208	CcSEcCtD
Lapatinib—Rash—Etoposide—muscle cancer	0.000387	0.00207	CcSEcCtD
Lapatinib—Dermatitis—Etoposide—muscle cancer	0.000386	0.00206	CcSEcCtD
Lapatinib—Headache—Etoposide—muscle cancer	0.000384	0.00205	CcSEcCtD
Lapatinib—Myalgia—Methotrexate—muscle cancer	0.000383	0.00205	CcSEcCtD
Lapatinib—Arthralgia—Methotrexate—muscle cancer	0.000383	0.00205	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000381	0.00203	CcSEcCtD
Lapatinib—Back pain—Doxorubicin—muscle cancer	0.000377	0.00201	CcSEcCtD
Lapatinib—Anaphylactic shock—Methotrexate—muscle cancer	0.000367	0.00196	CcSEcCtD
Lapatinib—Infection—Methotrexate—muscle cancer	0.000365	0.00195	CcSEcCtD
Lapatinib—Nausea—Etoposide—muscle cancer	0.000364	0.00195	CcSEcCtD
Lapatinib—Nervous system disorder—Methotrexate—muscle cancer	0.00036	0.00192	CcSEcCtD
Lapatinib—Anaemia—Doxorubicin—muscle cancer	0.00036	0.00192	CcSEcCtD
Lapatinib—Skin disorder—Methotrexate—muscle cancer	0.000357	0.00191	CcSEcCtD
Lapatinib—Anorexia—Methotrexate—muscle cancer	0.00035	0.00187	CcSEcCtD
Lapatinib—Leukopenia—Doxorubicin—muscle cancer	0.000349	0.00186	CcSEcCtD
Lapatinib—Palpitations—Doxorubicin—muscle cancer	0.000344	0.00184	CcSEcCtD
Lapatinib—Cough—Doxorubicin—muscle cancer	0.00034	0.00182	CcSEcCtD
Lapatinib—EGFR—PI-3K cascade—KIT—muscle cancer	0.000337	0.00124	CbGpPWpGaD
Lapatinib—ERBB4—DAP12 interactions—MDM2—muscle cancer	0.000337	0.00124	CbGpPWpGaD
Lapatinib—ERBB4—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000337	0.00124	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by FGFR in disease—MDM2—muscle cancer	0.000337	0.00124	CbGpPWpGaD
Lapatinib—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000336	0.00124	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000336	0.00124	CbGpPWpGaD
Lapatinib—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000335	0.00179	CcSEcCtD
Lapatinib—ERBB2—Signaling by PDGF—MDM2—muscle cancer	0.000334	0.00123	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by EGFR—MDM2—muscle cancer	0.000334	0.00123	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KIDINS220—muscle cancer	0.000333	0.00123	CbGpPWpGaD
Lapatinib—Insomnia—Methotrexate—muscle cancer	0.000332	0.00178	CcSEcCtD
Lapatinib—Myalgia—Doxorubicin—muscle cancer	0.000332	0.00177	CcSEcCtD
Lapatinib—Arthralgia—Doxorubicin—muscle cancer	0.000332	0.00177	CcSEcCtD
Lapatinib—ERBB4—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000331	0.00122	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—FOXO1—muscle cancer	0.00033	0.00122	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.00033	0.00122	CbGpPWpGaD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00033	0.00176	CcSEcCtD
Lapatinib—ERBB4—Signaling by PDGF—MDM2—muscle cancer	0.000329	0.00121	CbGpPWpGaD
Lapatinib—EGFR—PI3K/AKT activation—KIT—muscle cancer	0.000329	0.00121	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KIDINS220—muscle cancer	0.000328	0.00121	CbGpPWpGaD
Lapatinib—Dyspnoea—Methotrexate—muscle cancer	0.000328	0.00175	CcSEcCtD
Lapatinib—EGFR—GAB1 signalosome—KIT—muscle cancer	0.000326	0.0012	CbGpPWpGaD
Lapatinib—Dyspepsia—Methotrexate—muscle cancer	0.000323	0.00173	CcSEcCtD
Lapatinib—ERBB2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000322	0.00118	CbGpPWpGaD
Lapatinib—Decreased appetite—Methotrexate—muscle cancer	0.000319	0.00171	CcSEcCtD
Lapatinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—muscle cancer	0.000319	0.00117	CbGpPWpGaD
Lapatinib—Anaphylactic shock—Doxorubicin—muscle cancer	0.000318	0.0017	CcSEcCtD
Lapatinib—PIK3C2B—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.000318	0.00117	CbGpPWpGaD
Lapatinib—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000317	0.00169	CcSEcCtD
Lapatinib—Fatigue—Methotrexate—muscle cancer	0.000317	0.00169	CcSEcCtD
Lapatinib—ERBB2—B Cell Activation—MDM2—muscle cancer	0.000316	0.00117	CbGpPWpGaD
Lapatinib—Infection—Doxorubicin—muscle cancer	0.000316	0.00169	CcSEcCtD
Lapatinib—EGFR—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.000316	0.00116	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways in Glioblastoma—CDKN2A—muscle cancer	0.000315	0.00116	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000313	0.00115	CbGpPWpGaD
Lapatinib—Nervous system disorder—Doxorubicin—muscle cancer	0.000312	0.00167	CcSEcCtD
Lapatinib—ERBB4—B Cell Activation—MDM2—muscle cancer	0.000312	0.00115	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—FOXO1—muscle cancer	0.000311	0.00115	CbGpPWpGaD
Lapatinib—ERBB2—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.00031	0.00114	CbGpPWpGaD
Lapatinib—Skin disorder—Doxorubicin—muscle cancer	0.000309	0.00165	CcSEcCtD
Lapatinib—PI4KB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.000307	0.00113	CbGpPWpGaD
Lapatinib—EGFR—SHP2 signaling—VEGFA—muscle cancer	0.000306	0.00113	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways in Glioblastoma—MDM2—muscle cancer	0.000306	0.00113	CbGpPWpGaD
Lapatinib—Anorexia—Doxorubicin—muscle cancer	0.000303	0.00162	CcSEcCtD
Lapatinib—ERBB2—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000303	0.00112	CbGpPWpGaD
Lapatinib—Gastrointestinal pain—Methotrexate—muscle cancer	0.0003	0.0016	CcSEcCtD
Lapatinib—ERBB2—Innate Immune System—FOXO4—muscle cancer	0.0003	0.0011	CbGpPWpGaD
Lapatinib—ERBB4—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000298	0.0011	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—FOXO1—muscle cancer	0.000297	0.00109	CbGpPWpGaD
Lapatinib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000296	0.00109	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by NGF—KIT—muscle cancer	0.000296	0.00109	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—FOXO1—muscle cancer	0.000296	0.00109	CbGpPWpGaD
Lapatinib—EGFR—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.000296	0.00109	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—FOXO4—muscle cancer	0.000295	0.00109	CbGpPWpGaD
Lapatinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	0.000294	0.00108	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—FOXO1—muscle cancer	0.000294	0.00108	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—FOXO1—muscle cancer	0.000293	0.00108	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by NGF—KIT—muscle cancer	0.000291	0.00107	CbGpPWpGaD
Lapatinib—Abdominal pain—Methotrexate—muscle cancer	0.00029	0.00155	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00029	0.00155	CcSEcCtD
Lapatinib—ERBB2—DNA Damage Response (only ATM dependent)—TP53—muscle cancer	0.000289	0.00106	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	0.000288	0.00106	CbGpPWpGaD
Lapatinib—Insomnia—Doxorubicin—muscle cancer	0.000288	0.00154	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—FOXO4—muscle cancer	0.000288	0.00106	CbGpPWpGaD
Lapatinib—EGFR—Androgen receptor signaling pathway—MDM2—muscle cancer	0.000286	0.00105	CbGpPWpGaD
Lapatinib—Dyspnoea—Doxorubicin—muscle cancer	0.000284	0.00152	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—FOXO4—muscle cancer	0.000283	0.00104	CbGpPWpGaD
Lapatinib—Dyspepsia—Doxorubicin—muscle cancer	0.00028	0.0015	CcSEcCtD
Lapatinib—Decreased appetite—Doxorubicin—muscle cancer	0.000277	0.00148	CcSEcCtD
Lapatinib—EGFR—Signaling by FGFR in disease—FOXO1—muscle cancer	0.000275	0.00101	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—FOXO1—muscle cancer	0.000275	0.00101	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.000275	0.00101	CbGpPWpGaD
Lapatinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000275	0.00147	CcSEcCtD
Lapatinib—Fatigue—Doxorubicin—muscle cancer	0.000274	0.00147	CcSEcCtD
Lapatinib—EGFR—Signaling by EGFR—FOXO1—muscle cancer	0.000273	0.00101	CbGpPWpGaD
Lapatinib—Constipation—Doxorubicin—muscle cancer	0.000272	0.00145	CcSEcCtD
Lapatinib—Hypersensitivity—Methotrexate—muscle cancer	0.000271	0.00145	CcSEcCtD
Lapatinib—EGFR—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.00027	0.000996	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—FOXO1—muscle cancer	0.000269	0.000992	CbGpPWpGaD
Lapatinib—EGFR—PI-3K cascade—MDM2—muscle cancer	0.000265	0.000977	CbGpPWpGaD
Lapatinib—Asthenia—Methotrexate—muscle cancer	0.000264	0.00141	CcSEcCtD
Lapatinib—TAP1—Immune System—KIT—muscle cancer	0.000261	0.000963	CbGpPWpGaD
Lapatinib—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00026	0.00139	CcSEcCtD
Lapatinib—Pruritus—Methotrexate—muscle cancer	0.00026	0.00139	CcSEcCtD
Lapatinib—EGFR—PI3K/AKT activation—MDM2—muscle cancer	0.000259	0.000953	CbGpPWpGaD
Lapatinib—EGFR—GAB1 signalosome—MDM2—muscle cancer	0.000257	0.000946	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CD34—muscle cancer	0.000257	0.000946	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—FOXO1—muscle cancer	0.000255	0.000939	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—FOXO4—muscle cancer	0.000254	0.000935	CbGpPWpGaD
Lapatinib—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000254	0.000935	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CD34—muscle cancer	0.000253	0.000932	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—KIT—muscle cancer	0.000252	0.000927	CbGpPWpGaD
Lapatinib—Abdominal pain—Doxorubicin—muscle cancer	0.000251	0.00134	CcSEcCtD
Lapatinib—Diarrhoea—Methotrexate—muscle cancer	0.000251	0.00134	CcSEcCtD
Lapatinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	0.000251	0.000924	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—FOXO1—muscle cancer	0.000251	0.000923	CbGpPWpGaD
Lapatinib—ERBB2—Focal Adhesion—VEGFA—muscle cancer	0.000245	0.000903	CbGpPWpGaD
Lapatinib—EGFR—ErbB Signaling Pathway—TP53—muscle cancer	0.000245	0.000903	CbGpPWpGaD
Lapatinib—ERBB2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000244	0.0009	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.000244	0.000898	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000242	0.000892	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—MYOD1—muscle cancer	0.000241	0.000889	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—KIT—muscle cancer	0.000241	0.000887	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—KIT—muscle cancer	0.000237	0.000873	CbGpPWpGaD
Lapatinib—Hypersensitivity—Doxorubicin—muscle cancer	0.000234	0.00125	CcSEcCtD
Lapatinib—Vomiting—Methotrexate—muscle cancer	0.000234	0.00125	CcSEcCtD
Lapatinib—ERBB2—Signaling by NGF—MDM2—muscle cancer	0.000233	0.000858	CbGpPWpGaD
Lapatinib—Rash—Methotrexate—muscle cancer	0.000232	0.00124	CcSEcCtD
Lapatinib—Dermatitis—Methotrexate—muscle cancer	0.000231	0.00124	CcSEcCtD
Lapatinib—Headache—Methotrexate—muscle cancer	0.00023	0.00123	CcSEcCtD
Lapatinib—ERBB4—Signaling by NGF—MDM2—muscle cancer	0.000229	0.000845	CbGpPWpGaD
Lapatinib—Asthenia—Doxorubicin—muscle cancer	0.000228	0.00122	CcSEcCtD
Lapatinib—CYP2C19—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000226	0.000834	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—KIT—muscle cancer	0.000226	0.000834	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—KIT—muscle cancer	0.000225	0.00083	CbGpPWpGaD
Lapatinib—Pruritus—Doxorubicin—muscle cancer	0.000225	0.0012	CcSEcCtD
Lapatinib—EGFR—Signaling by ERBB2—KIT—muscle cancer	0.000224	0.000825	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—KIT—muscle cancer	0.000223	0.000821	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—FOXO1—muscle cancer	0.000221	0.000815	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—MED12—muscle cancer	0.000221	0.000813	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—PTGS2—muscle cancer	0.00022	0.000812	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.00022	0.00081	CbGpPWpGaD
Lapatinib—Nausea—Methotrexate—muscle cancer	0.000218	0.00117	CcSEcCtD
Lapatinib—ERBB4—Innate Immune System—FOXO1—muscle cancer	0.000218	0.000803	CbGpPWpGaD
Lapatinib—Diarrhoea—Doxorubicin—muscle cancer	0.000218	0.00116	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—FOXO1—muscle cancer	0.000212	0.000783	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—KIT—muscle cancer	0.00021	0.000773	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—KIT—muscle cancer	0.00021	0.000773	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.00021	0.000773	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—FOXO1—muscle cancer	0.000209	0.000771	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—KIT—muscle cancer	0.000208	0.000766	CbGpPWpGaD
Lapatinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	0.000206	0.00076	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000206	0.000759	CbGpPWpGaD
Lapatinib—TAP1—Immune System—MDM2—muscle cancer	0.000206	0.000758	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—KIT—muscle cancer	0.000205	0.000756	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CD34—muscle cancer	0.000205	0.000754	CbGpPWpGaD
Lapatinib—Vomiting—Doxorubicin—muscle cancer	0.000202	0.00108	CcSEcCtD
Lapatinib—Rash—Doxorubicin—muscle cancer	0.000201	0.00107	CcSEcCtD
Lapatinib—Dermatitis—Doxorubicin—muscle cancer	0.0002	0.00107	CcSEcCtD
Lapatinib—EGFR—Direct p53 effectors—MDM2—muscle cancer	0.000199	0.000734	CbGpPWpGaD
Lapatinib—Headache—Doxorubicin—muscle cancer	0.000199	0.00106	CcSEcCtD
Lapatinib—EGFR—Signaling by SCF-KIT—MDM2—muscle cancer	0.000198	0.00073	CbGpPWpGaD
Lapatinib—ERBB2—Disease—ENO2—muscle cancer	0.000198	0.000728	CbGpPWpGaD
Lapatinib—ERBB4—Disease—ENO2—muscle cancer	0.000195	0.000717	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—KIT—muscle cancer	0.000194	0.000715	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.00019	0.000698	CbGpPWpGaD
Lapatinib—Nausea—Doxorubicin—muscle cancer	0.000189	0.00101	CcSEcCtD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.000188	0.000691	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—FOXO1—muscle cancer	0.000188	0.000691	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—MDM2—muscle cancer	0.000187	0.000687	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000186	0.000684	CbGpPWpGaD
Lapatinib—ERBB2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000184	0.00068	CbGpPWpGaD
Lapatinib—ERBB2—Disease—HMGA1—muscle cancer	0.00018	0.000662	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—MDM2—muscle cancer	0.000178	0.000657	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—MDM2—muscle cancer	0.000177	0.000653	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000177	0.000652	CbGpPWpGaD
Lapatinib—ERBB4—Disease—HMGA1—muscle cancer	0.000177	0.000652	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—MDM2—muscle cancer	0.000176	0.00065	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—MDM2—muscle cancer	0.000176	0.000647	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways in Glioblastoma—TP53—muscle cancer	0.000175	0.000646	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—FOXO4—muscle cancer	0.000174	0.000643	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000173	0.000638	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—FOXO4—muscle cancer	0.000172	0.000633	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—KIT—muscle cancer	0.000169	0.000621	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—KIT—muscle cancer	0.000166	0.000612	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—MDM2—muscle cancer	0.000165	0.000609	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000165	0.000609	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—MDM2—muscle cancer	0.000165	0.000609	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—MDM2—muscle cancer	0.000164	0.000603	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000162	0.000598	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—KIT—muscle cancer	0.000162	0.000596	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—MDM2—muscle cancer	0.000162	0.000595	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KIDINS220—muscle cancer	0.000161	0.000594	CbGpPWpGaD
Lapatinib—ERBB2—Disease—FOXO4—muscle cancer	0.000161	0.000594	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—VEGFA—muscle cancer	0.00016	0.000589	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—KIT—muscle cancer	0.000159	0.000587	CbGpPWpGaD
Lapatinib—ERBB4—Disease—FOXO4—muscle cancer	0.000159	0.000585	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000155	0.000573	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—MDM2—muscle cancer	0.000153	0.000563	CbGpPWpGaD
Lapatinib—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.000151	0.000556	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.00015	0.000552	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000146	0.000539	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—FOXO4—muscle cancer	0.000145	0.000534	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—KIT—muscle cancer	0.000143	0.000526	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000142	0.000525	CbGpPWpGaD
Lapatinib—PIK3C2B—Metabolism—PTGS2—muscle cancer	0.000142	0.000522	CbGpPWpGaD
Lapatinib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000139	0.000514	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—FOXO4—muscle cancer	0.000139	0.000512	CbGpPWpGaD
Lapatinib—PI4KB—Metabolism—PTGS2—muscle cancer	0.000137	0.000504	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—MDM2—muscle cancer	0.000133	0.000489	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PTCH1—muscle cancer	0.000131	0.000483	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—TP53—muscle cancer	0.000131	0.000483	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—MDM2—muscle cancer	0.000131	0.000482	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PTCH1—muscle cancer	0.000129	0.000476	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—FOXO1—muscle cancer	0.000129	0.000475	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—MDM2—muscle cancer	0.000127	0.00047	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—FOXO1—muscle cancer	0.000127	0.000468	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—MDM2—muscle cancer	0.000126	0.000463	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD34—muscle cancer	0.000124	0.000457	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—FOXO1—muscle cancer	0.000121	0.000446	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—VEGFA—muscle cancer	0.000121	0.000445	CbGpPWpGaD
Lapatinib—ERBB2—Disease—FOXO1—muscle cancer	0.000119	0.000438	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—VEGFA—muscle cancer	0.000119	0.000437	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000118	0.000435	CbGpPWpGaD
Lapatinib—ERBB4—Disease—FOXO1—muscle cancer	0.000117	0.000432	CbGpPWpGaD
Lapatinib—EGFR—Direct p53 effectors—TP53—muscle cancer	0.000114	0.000421	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000114	0.000421	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—VEGFA—muscle cancer	0.000114	0.000421	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—FOXO4—muscle cancer	0.000113	0.000416	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—MDM2—muscle cancer	0.000113	0.000415	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—FOXO4—muscle cancer	0.000111	0.000409	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CNR1—muscle cancer	0.000111	0.000408	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CNR1—muscle cancer	0.000109	0.000402	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—TP53—muscle cancer	0.000108	0.000397	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PTCH1—muscle cancer	0.000107	0.000396	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—FOXO1—muscle cancer	0.000107	0.000394	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—FH—muscle cancer	0.000104	0.000383	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—FOXO1—muscle cancer	0.000103	0.000378	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000102	0.000375	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—TP53—muscle cancer	9.88e-05	0.000364	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—KIT—muscle cancer	9.82e-05	0.000362	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—KIT—muscle cancer	9.67e-05	0.000356	CbGpPWpGaD
Lapatinib—EGFR—Disease—ENO2—muscle cancer	9.55e-05	0.000352	CbGpPWpGaD
Lapatinib—ERBB2—Disease—KIT—muscle cancer	9.07e-05	0.000334	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CNR1—muscle cancer	9.06e-05	0.000334	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IGF2—muscle cancer	9.05e-05	0.000334	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—FH—muscle cancer	9e-05	0.000332	CbGpPWpGaD
Lapatinib—ERBB4—Disease—KIT—muscle cancer	8.93e-05	0.000329	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	8.92e-05	0.000329	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IGF2—muscle cancer	8.92e-05	0.000329	CbGpPWpGaD
Lapatinib—EGFR—Disease—HMGA1—muscle cancer	8.68e-05	0.00032	CbGpPWpGaD
Lapatinib—EGFR—Immune System—FOXO4—muscle cancer	8.44e-05	0.000311	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—FOXO1—muscle cancer	8.33e-05	0.000307	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—FOXO1—muscle cancer	8.21e-05	0.000302	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—KIT—muscle cancer	8.15e-05	0.0003	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—FH—muscle cancer	8.03e-05	0.000296	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	7.85e-05	0.000289	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—FH—muscle cancer	7.84e-05	0.000289	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—KIT—muscle cancer	7.83e-05	0.000288	CbGpPWpGaD
Lapatinib—EGFR—Disease—FOXO4—muscle cancer	7.79e-05	0.000287	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—VEGFA—muscle cancer	7.73e-05	0.000285	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—MDM2—muscle cancer	7.73e-05	0.000285	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—MDM2—muscle cancer	7.62e-05	0.000281	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	7.56e-05	0.000279	CbGpPWpGaD
Lapatinib—ERBB2—Disease—MDM2—muscle cancer	7.14e-05	0.000263	CbGpPWpGaD
Lapatinib—ERBB4—Disease—MDM2—muscle cancer	7.03e-05	0.000259	CbGpPWpGaD
Lapatinib—ERBB2—Disease—PTGS2—muscle cancer	6.88e-05	0.000254	CbGpPWpGaD
Lapatinib—ERBB4—Disease—PTGS2—muscle cancer	6.78e-05	0.00025	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—MDM2—muscle cancer	6.42e-05	0.000236	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KIT—muscle cancer	6.35e-05	0.000234	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTCH1—muscle cancer	6.34e-05	0.000234	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KIT—muscle cancer	6.25e-05	0.00023	CbGpPWpGaD
Lapatinib—EGFR—Immune System—FOXO1—muscle cancer	6.23e-05	0.00023	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—MDM2—muscle cancer	6.16e-05	0.000227	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.96e-05	0.000219	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—MED12—muscle cancer	5.87e-05	0.000216	CbGpPWpGaD
Lapatinib—EGFR—Disease—FOXO1—muscle cancer	5.75e-05	0.000212	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—VEGFA—muscle cancer	5.52e-05	0.000203	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—FOXO4—muscle cancer	5.45e-05	0.000201	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CNR1—muscle cancer	5.35e-05	0.000197	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ENO2—muscle cancer	5.35e-05	0.000197	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—MED12—muscle cancer	5.08e-05	0.000187	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MDM2—muscle cancer	5e-05	0.000184	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MDM2—muscle cancer	4.92e-05	0.000181	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—FH—muscle cancer	4.83e-05	0.000178	CbGpPWpGaD
Lapatinib—EGFR—Immune System—KIT—muscle cancer	4.75e-05	0.000175	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ENO2—muscle cancer	4.64e-05	0.000171	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—MED12—muscle cancer	4.54e-05	0.000167	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.5e-05	0.000166	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—MED12—muscle cancer	4.43e-05	0.000163	CbGpPWpGaD
Lapatinib—EGFR—Disease—KIT—muscle cancer	4.38e-05	0.000161	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IGF2—muscle cancer	4.38e-05	0.000161	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ENO2—muscle cancer	4.14e-05	0.000152	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ENO2—muscle cancer	4.04e-05	0.000149	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—FOXO1—muscle cancer	4.03e-05	0.000148	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—VEGFA—muscle cancer	3.8e-05	0.00014	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—VEGFA—muscle cancer	3.74e-05	0.000138	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MDM2—muscle cancer	3.74e-05	0.000138	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.63e-05	0.000134	CbGpPWpGaD
Lapatinib—EGFR—Disease—MDM2—muscle cancer	3.45e-05	0.000127	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTGS2—muscle cancer	3.33e-05	0.000123	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.24e-05	0.000119	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KIT—muscle cancer	3.07e-05	0.000113	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—muscle cancer	2.87e-05	0.000106	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—muscle cancer	2.83e-05	0.000104	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—MED12—muscle cancer	2.73e-05	0.000101	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ENO2—muscle cancer	2.49e-05	9.17e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MDM2—muscle cancer	2.42e-05	8.9e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTGS2—muscle cancer	1.86e-05	6.87e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—VEGFA—muscle cancer	1.84e-05	6.76e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTGS2—muscle cancer	1.61e-05	5.95e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTGS2—muscle cancer	1.44e-05	5.31e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTGS2—muscle cancer	1.41e-05	5.18e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—muscle cancer	1.39e-05	5.11e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS2—muscle cancer	8.67e-06	3.19e-05	CbGpPWpGaD
